ClinicalTrials.gg
CompletedNCT02065609Updated Oct 13, 2022Results posted

89ZrTrastuzumab Breast Imaging With Positron Emission Tomography

An Early Phase 1 interventional study of 89Zr-Trastuzumab Human Dosimetry and Safety and HER2 Positive Lesion Detection and Safety in Breast Cancer, sponsored by Washington University School of Medicine. Completed at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-10-13.

Sponsored by Washington University School of Medicine · Early Phase 1, Interventional, and Diagnostic

How we know · 2 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
52
Allocation
Non-randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 80 studies in Breast Neoplasms by Washington University School of Medicine — 18 open to participants now, 22 under way, none of them phase 3. Breast Neoplasms · Washington University School of Medicine.

Enrollment
39th of 74
52 · median 55
Started
2014
with 5 others
Phase 1
17 of 80
1 open now
Registered
32nd of 80
by date

Among the 80 studies in Breast Neoplasms by Washington University School of Medicine, this one is the 39th largest by enrollment of the 74 interventional ones that give a count, is one of 6 that started in 2014, is one of 17 in phase 1, and was the 32nd registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

18 of the 80 studies in Breast Neoplasms by Washington University School of Medicine are open now, in 1 country. Recruiting first, the newest first:

13 more — sign in →

By country, each count listing its studies:

All 18 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 80 studies in Breast Neoplasms by Washington University School of Medicine, or all of them as a file.
02

Study summary

The main purpose of this study is to see if Positron Emission Tomography (PET-Imaging) with 89Zr labeled trastuzumab can detect trastuzumab (HER2) positive breast cancer.

03

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • Trastuzumab
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female patients 18 years of age or older
  • Cohort 1: Her2-positive (defined as 3+) or FISH :CEP17 ratio > 2 proven breast cancer
  • Cohort 2: Her2-positive (defined as 3+) or FISH HER2:CEP17 ratio > 2 OR HER2negative (0 or 1+, 2+ and FISH negative) biopsy-proven breast cancer
  • Primary or recurrent/ lesion size ≥ 1.5 cm as determined by imaging studies (ultrasonography, mammography, CT or MRI) or physical examination
  • Able to give
  • Not currently pregnant or nursing: Subject must be surgically sterile (has had a documented bilateral oophorectomy and/or documented hysterectomy), (cessation of menses for more than 1 year), non-lactating, or of for whom a urine pregnancy test (with the test performed within the 24 hour period immediately prior to administration of 89Zr-trastuzumab) is negative
  • Patients currently receiving trastuzumab therapy with or without other types of systemic therapy can participate if their disease progresses (development of new lesion(s) or worsening of known lesion(s) based on imaging modalities or physical examination.

Exclusion criteria

Exclusion Criteria:

  • Patients with other invasive , with the exception of non- melanoma skin cancer, who had (or have) any evidence of the other cancer present within the last 5 years
  • Unable to tolerate 60 min of PET imaging per imaging session
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Early Phase 1
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
52 participants (actual)

Study arms

  • Experimental
    Cohort 1

    89Zr-Trastuzumab Human Dosimetry and Safety

    Drug: 89Zr-Trastuzumab Human Dosimetry and Safety · Drug: HER2 Positive Lesion Detection and Safety

  • Experimental
    Cohort 2: Lesion Detection and Safety

    HER2 Positive Lesion Detection and Safety

    Drug: 89Zr-Trastuzumab Human Dosimetry and Safety · Drug: HER2 Positive Lesion Detection and Safety

Interventions

  • Drug89Zr-Trastuzumab Human Dosimetry and Safety

    PET Imaging following administration of 89Zr labeled Trastuzumab for calculation of human dosimetry and overall safety

  • DrugHER2 Positive Lesion Detection and Safety

    Detection of HER2 Positive Breast Cancer with 89Zr Labeled Trastuzumab and PET imaging

This study also gives TrastuzumabStudies of TrastuzumabTrastuzumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events as a Measure of Safety and Tolerability After 89Zr-Trastuzumab Administration

    Subjects medical record was followed for 30 days following 89Zr-Trastuzumab Administration for AE Assessment with AE being defined as Any unfavorable medical occurrence in a human subject who receives 89Zr-Trastuzumab and PET/CT imaging, including any abnormal sign, symptom, or disease. The event does not necessarily have to be causally related to injection of 89Zr-Trastuzumab or PET/CT imaging to qualify as an adverse event, just temporally related.

    Time frame: 30 Days following 89Zr-Trastuzumab Administration

07

Results

Posted Oct 6, 2022

Participant flow

Study first enrollment occurred in February 2014 and closed to enrollment 31 December 2017. Subjects were recruited from those patients being seen by medical oncology at Siteman Cancer Center. Planned enrollment was 67 participants with a total of 52 subjects enrolled with evaluable data at the end of the grant period.

Participant flow — Overall Study
MilestoneCohort 1Cohort 2: Lesion Detection and Safety
Started1240
Completed1240
Not completed00

Outcome measures

PrimaryNumber of Participants With Adverse Events as a Measure of Safety and Tolerability After 89Zr-Trastuzumab Administration

Subjects medical record was followed for 30 days following 89Zr-Trastuzumab Administration for AE Assessment with AE being defined as Any unfavorable medical occurrence in a human subject who receives 89Zr-Trastuzumab and PET/CT imaging, including any abnormal sign, symptom, or disease. The event does not necessarily have to be causally related to injection of 89Zr-Trastuzumab or PET/CT imaging to qualify as an adverse event, just temporally related.

Time frame:
30 Days following 89Zr-Trastuzumab Administration
Reported as:
Number · participants
Number of Participants With Adverse Events as a Measure of Safety and Tolerability After 89Zr-Trastuzumab Administration
participantsCohort 1Cohort 2: Lesion Detection and Safety
Number of Participants With Adverse Events as a Measure of Safety and Tolerability After 89Zr-Trastuzumab Administration11

Adverse events

Collected over Subjects were monitored for adverse events for the 30 days following 89Zr-Trastuzumab administration. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 10/12 (0%)0/12 (0%)1/12 (8.3%)
Cohort 2: Lesion Detection and Safety0/40 (0%)0/40 (0%)1/40 (2.5%)
Most frequent other events
Most frequent other events
EventCohort 1Cohort 2: Lesion Detection and Safety
non-neutropenic feverGeneral disorders1/120/40
Flu Like SymptomsGeneral disorders1/120/40
Acute Kidney InjuryRenal and urinary disorders0/121/40
SepsisInfections and infestations0/121/40

Baseline characteristics

Age, Customized
Age, Customized(years)Cohort 1Cohort 2: Lesion Detection and SafetyTotal
Mean56.9 (29 to 74)56 (37 to 78)56.5 (29 to 78)
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1Cohort 2: Lesion Detection and SafetyTotal
Female124052
Male000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort 1Cohort 2: Lesion Detection and SafetyTotal
Hispanic or Latino011
Not Hispanic or Latino123951
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)Cohort 1Cohort 2: Lesion Detection and SafetyTotal
United States124052
08

Study locations

1 site
  • Washington University School of Medicine @ Barnes-Jewish Hospital
    Saint Louis, Missouri 63110, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2014, a primary completion of Dec 2017 and a completion of Feb 2018. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2022, 4 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 5, 2014
First posted
Feb 19, 2014
Start
Feb 2014
Primary completionActual
Dec 31, 2017
CompletionActual
Feb 13, 2018
Results first posted
Oct 6, 2022
Last update
Oct 13, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 13, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02065609
Responsible party
Farrokh Dehdashti (Professor of Radiology, Washington University School of Medicine) — Principal investigator
First posted
Feb 19, 2014
Start date
Feb 2014
Primary completion
Dec 31, 2017
Completion
Feb 13, 2018
Results posted
Oct 6, 2022
Last update
Oct 13, 2022

Study contacts

Farrokh Dehdashti, MD
principal investigator · Washington University School of Medicine

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion